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IgA is present in the skin in several dermatoses,
including dermatitis herpetiformis, linear IgA bullous
dermatosis, and Henoch-Schoenlein purpura. The neu-
trophilic in¢ltration in the area of the IgA deposition
suggests that IgA is responsible for the associated in-
£ammatory events. The mechanism for this process is
unproven, but is likely to involve IgA-mediated neutro-
phil chemotaxis with inhibition of chemotaxis by dap-
sone. Elucidation of the mechanism of IgA-mediated
in£ammation will require an animal model. We
have established a model for linear IgA bullous
dermatosis as a prototype disease to be studied. IgA
mouse monoclonal antibodies against a linear IgA bul-
lous dermatosis antigen have been passively transferred
to SCID mice with human skin grafts. This has pro-
duced neutrophil in¢ltration and basement membrane
vesiculation in 4 of 12 mice tested.We conclude that an
animal model for the pathogenesis of IgA dermatoses
with IgA deposition and in£ammation can be produced
by passive transfer of mouse IgA antibodies against a
linear IgA antigen. Keywords: J Investig Dermatol Symp
Proc 9:47^51, 2004
IGA IN AUTOIMMUNE DISORDERS OF THE SKIN
T
he hallmark of IgA autoimmune disorders of the
skin is the deposition of IgA in tissue at the site of
the in£ammatory process. In these disorders, IgA
is the only or the predominant immunoglobulin
detected in the skin. Next there is in¢ltration of
neutrophils into the skin and compromise of the function of
structural proteins. This produces vesiculation or blood vessel de-
struction that is clinically evident as vesicles, bullae, and purpura.
Dapsone usually inhibits the in£ammatory process, but it does
not inhibit the deposition of IgA in the skin.
Tissue-speci¢c IgA antibodies in the serum may be identi¢ed.
This is the case in linear IgA bullous dermatosis (LABD) and IgA
pemphigus. In dermatitis herpetiformis (DH), IgA vasculitis, and
bullous lupus erythematosus, however, no tissue-speci¢c antibo-
dies have been identi¢ed in the circulation. The IgA dermatoses
are listed inTable 1.
CONTRAST WITH IGG DERMATOSES
Many of the IgA dermatoses have IgG-associated counterparts.
The contrast between the IgA dermatoses and the analogous IgG
dermatoses also provides insight into pathogenic factors related to
antibody class speci¢city.
Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) de-
monstrate cell surface deposition of IgG on epithelial cells. These
antibodies bind the cadherins desmoglein 3 and desmoglein 1, re-
spectively (Emery et al, 1995; Harman et al, 2000). The acantholy-
tic process seems to be one of direct destruction of the cadherins,
which maintain epithelial cell adherence, or possibly an antibody-
stimulated proteolytic process that destroys the adherence proteins.
Fixation of complement and in¢ltration of in£ammatory cells is
not essential to the acantholytic process. IgA pemphigus foliaceus
(referred to as the subcorneal pustular variant of IgA pemphigus)
and IgA PV (referred to as the intraepidermal variant of IgA pem-
phigus) demonstrate cell surface deposition of IgA on epithelial
cells. IgA pemphigus antibodies only bind infrequently to desmo-
gleins, however, but more often bind to another class of cadherins
termed desmocollins (Hashimoto et al, 2001). They do not seem to
stimulate acantholysis by their physical presence, but require the
in¢ltration of neutrophils for acantholysis and vesiculation. The
pathogenic process is clearly di¡erent for IgG and IgA dermatoses.
Autoantigen stimulation of the IgA immune system produces a res-
ponse to a neighboring autoantigen. The amino acid sequence of
the alpha chain of IgA somehow initiates an entirely di¡erent pro-
cess than that of the gamma chain.
In a similar manner, basement membrane antibody^related
diseases di¡er in their antigenic speci¢city and presumed patho-
genesis. Bullous pemphigoid (BP) and the lamina lucida type of
LABD both demonstrate lamina lucida deposition of immuno-
globulin and are associated with BMZ vesiculation.The antigenic
speci¢city di¡ers, however. Pathogenic epitopes for the IgG im-
mune response are believed to be in the MCW-1 region of the
Table1. IgA Dermatoses
Dermatitis herpetiformis
Linear IgA bullous dermatosis
Chronic bullous disease of childhood
Linear IgA/IgG bullous dermatosis
Ocular cicatricial pemphigoid
IgA pemphigus (intraepidermal type)
IgA pemphigus (subcorneal pustular dermatosis type)
IgAvasculitis (Henoch-Schoenlein purpura)
Bullous lupus erythematosus
Correspondence and reprint requests to: John J. Zone, MD Department
of Dermatology, UUHSC Salt Lake City, UT, 84132. E-mail: Zone@
derm.med.utah.edu
Abbreviations: AB, antibody; BMZ, basement membrane zone; BP, bul-
lous pemphigoid; DH, dermatitis herpetiformis; EBA, epidermolysis bul-
losa acquisita; LABD, linear IgA bullous dermatosis; Mab, monoclonal
antibody; PF, pemphigus foliacious; PV, pemphigus vulgarous;
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NC16 domain of BPAg2 (BP180), whereas the epitopes that have
stimulated an IgA immune response are toward the carboxy ter-
minus of the same molecule (Fig 1) (Giudice et al, 1993; Zone et al,
1998). Epitopes in LABD appear to become antigenic only when
the molecule has been proteolytically cleaved. The typical in£am-
matory cell in BP is the eosinophil with an admixture of neutro-
phils and mononuclear cells. There is also a ‘‘cell-poor’’ histologic
variant of pemphigoid. In contrast, LABD is invariably associated
with the intense in¢ltration of neutrophils at the BMZ and in
dermal papillae identical to that of DH. No cell-poor variant has
been described. Epidermolysis bullosa acquisita (EBA) and the sub-
lamina densa type of LABD are analogous in that antibody deposi-
tion is in the sublamina densa area in both conditions. In EBA the
antigenic speci¢city for IgG antibodies has been identi¢ed as type
VII collagen (Lapiere et al, 1993). In the sublamina densa variant of
LABD, some cases have been reported in which patient serum IgA
antibodies bind to typeVII collagen (Zambruno et al, 1994).We had
the opportunity to test 11 sera with antibodies binding to the dermal
side of BMZ split skin, however, and only 1 of those sera was found
to bind to type VII collagen on immunoblot. It seems likely that
other antigens may be involved in these dermal LABD patients.We
were not able to establish any other antigenic speci¢city on immu-
noblot. Classically, both EBA and sublamina densa LABD have an
intense in¢ltration of neutrophils.Why the nature of the in£amma-
tory in¢ltrate should vary from BP to EBA is likewise unclear.
LINEAR IGA/IGG DERMATOSES
Frequently, patients with linear deposition of immunoglobulin
along the BMZ demonstrate both IgG and IgA deposition. The
exact terminology to describe these cases is di⁄cult. Convention
has dictated that these diseases be described as BP if IgG is the
predominant immunoglobulin, or as LABD if IgA is the predo-
minant immunoglobulin. It has been our belief, however, that
these represent diseases di¡erent from true BP or true LABD. If,
indeed, the antibody deposition at the BMZ is responsible for the
pathogenesis of the disease, it makes sense that a combination of
two immunoglobulin classes would produce a di¡erent patho-
genesis than a single antibody class.We investigated the antigenic
speci¢city in these disorders and found that for these basement
membrane antibodies it is mixed (Zone et al, 1994). Studying the
pathogenesis of disorders such as these will be accomplished only
when multiple speci¢c antibodies are available for passive transfer
experiments. In the meantime, it is our opinion that these diseases
should be called linear IgA/IgG bullous dermatosis (LAGBD),
rather than be named on the basis of the predominant immuno-
globulin.
DERMATITIS HERPETIFORMIS
Dermatitus herpetiformis (DH) has no real analogy in any of the
IgG bullous dermatoses.Virtually all patients with DH have gran-
ular IgA deposition along the basement membrane or in dermal
papillary tips. Because the in£ammatory in¢ltrate is predomi-
nantly neutrophilic, the connection between IgA deposition and
neutrophil in¢ltration is again demonstrated. Likewise, respon-
siveness to dapsone is one of the hallmarks of DH and empha-
sizes the unique nature of IgA dermatoses.
DH patients have a unique HLA type (HLA DQ2
A1501B1201). This is present in greater than 90% of patients
and appears to be central to the antigen recognition process in
which gliadin initiates a systemic immune response. This antigen
recognition is essential in the pathogenesis of both DH and celiac
disease which shares DH’s immunogenetic predisposition. Vir-
tually all patients with DH have some degree of celiac disease.
This covers the histologic spectrum of jejunal mucosal in£amma-
tion and ranges from minimal intraepithelial lymphocyte in¢l-
tration with normal villi to an entirely £at intestinal mucosa. As
such, DH can be considered an extraintestinal manifestation of
celiac disease (Zone, 1991).
Until recently, no consistent serologic di¡erence could be es-
tablished that di¡erentiated DH from celiac disease, and thus
there was no serologic explanation for the deposition of IgA in
dermal papillae. There was also no evidence of an antigen asso-
ciated with the deposition of granular IgA. Recently, Sardy
and colleagues found that IgA antibodies to epidermal transglu-
taminase are higher in patients with DH whereas IgA antibodies
to tissue transglutaminase are higher in celiac disease. Both
groups, however, may have some amount of antibody to each
transglutaminase antigen. The researchers also demonstrated that
DH skin contains epidermal transglutaminase in dermal papillae
that colocalizes with IgA (Sardy et al, 2002). Tissue transglutami-
nase was not found in association with the IgA in dermal papillae.
Patients with LABD were not found to have transglutaminase
in dermal papillae or at the BMZ, indicating that the distribution
was speci¢c for DH and did not colocalize or cross-react with
all cutaneous IgA. These ¢ndings speak strongly for epidermal
transglutaminase as an antigen in DH. Although this work
has been a landmark of progress in understanding DH, the exact
method by which the antigen/antibody complex reaches the
tissue has not yet been established and there is no animal
model for DH that has yet been developed as a result of this
work.
The responsiveness of DH to dapsone Responsiveness to
dapsone was once considered a diagnostic criterion for DH. A
number of other dermatoses clearly respond to dapsone,
however and the list of dapsone-responsive dermatoses includes
all of those listed in Table 1. One would think that dapsone’s
mechanism of action would be speci¢cally related to IgA
antibody and possibly related to neutrophil chemotaxis, but the
exact mechanism by which dapsone is e¡ective in these
dermatoses has not been established. It is known that dapsone
has no e¡ect on antibody or complement deposition. Dapsone
does inhibit neutrophil lysosomal activity and has been shown
to inhibit myeloperoxidase-mediated iodination. Dapsone has
also been shown to inhibit F-met-leu-phe-derived chemotaxis,
but not to inhibit chemotaxis to C5a.We evaluated the role of
dapsone in the neutrophil attachment assay and found that it
inhibits the adherence of neutrophils to basement membrane
Figure1. Diagrammatic representation of the
transmembrane hemidesmosomal protein BP180
(BPAg2). The primary site of antigenic reactivity for
bullous pemphigoid (MCW1) is di¡erent from that
for linear IgA bullous dermatosis (LABD97).
48 MEYER ETAL JID SYMPOSIUM PROCEEDINGS
zone antibody in a dose-dependent manner that covers the
pharmacologic range of serum dapsone levels (Thuong-Nguyen
et al, 1993). Nevertheless, this still does not explain how dapsone
inhibits chemotaxis of neutrophils into sites of IgA deposition.
AN ANIMAL MODEL OF IgA DERMOTOSES
Perhaps the biggest di¡erentiation between IgG and IgA derma-
toses is the fact that IgG autoantibodies have been proven to be
pathogenic to skin in an animal model. In 1982 Anhalt and collea-
gues published their landmark work demonstrating that human
pemphigus antibody passively transferred to neonatal mice pro-
duces acantholytic changes in mouse epithelium similar to those
found in human pemphigus (Anhalt et al, 1982). Similar experi-
ments with human BP antibodies were, however, unsuccessful
(Anhalt and Diaz, 1987). It was subsequently shown that the epi-
topes to which IgG BMZ antibodies to BPAg2 reacted were not
present in mouse skin. Liu and colleagues demonstrated that rabbit
IgG antibodies directed against mouse BPAg2 epitopes are patho-
genic when passively transferred to neonatal mice (Liu et al, 1993).
Our long-term goal has been to develop a mouse model for
the pathogenesis of IgA dermatoses. We initially attempted to
passively transfer the immunoglobulin fraction (ammonium sul-
fate precipitation fraction) of DH serum to athymic mice that
carried grafts of normal human skin. This approach did produce
occasional aggregates of IgA in dermal papillae, but IgA deposi-
tion was not consistent and the pattern was not that of granular
IgA seen in the dermal papillae in DH; neutrophil in¢ltration
and vesiculation were only noted on rare occasions.
As no circulating antibody responsible for the IgA deposition
in DH has been identi¢ed, we turned our attention to LABD. In
LABD, circulating IgA antibodies directed against cutaneous
basement membrane have been consistently identi¢ed by indirect
immuno£ourescence. Clinically, there are two types of LABD. In
the ¢rst type, the disease is very similar to DH in its clinical ap-
pearance and is characterized by grouped or scattered papulovesi-
cles and excoriations. In the second type, the disease is clinically
similar to BP, in which there are larger bullae and excoriations in
a more scattered distribution (Smith et al, 1995). These clinical
types occur in both the lamina lucida and sublamina densa
variants.
Ultrastructurally, there are also two subtypes of LABD: the la-
mina lucida type, in which IgA antibodies adhere to the epithelial
side of BMZ split skin, and the sublamina densa type, in which
IgA antibodies adhere to the dermal side of BMZ split skin. Our
early studies showed that the lamina lucida type is much more
common and that antibody was more likely to be identi¢ed in
the serum of these patients; consequently, all of our subsequent
studies focused on that LABD type.
In 1990, we reported the results of the immunoreactivity of
LABD sera on immunoblot (Zone et al, 1990). It had been pre-
viously stated that antigens were consistently identi¢ed that re-
acted with sera from patients with BP: BP230 (subsequently
termed BPAg1) and BP180 (subsequently termed BPAg2) (Stanley
et al, 1981; Diaz et al, 1990).We assumed that the reactivity of IgA
sera would be similar, but our studies identi¢ed predominant re-
activity with a 97-kDa protein found in epidermal extract. We
were not able to identify reactivity of LABD sera with BP180 or
BP230.We then studied patients with chronic bullous disease of
childhood and found that their IgA antibodies reacted in a simi-
lar manner (Zone et al, 1996). We concluded that the antigenic
speci¢city for linear IgA disease antibody was di¡erent from that
for BP antibody, but the nature of the 97-kDa protein was
unknown.
Marinkovich and colleagues developed a monoclonal antibody
that reacted with a 120-kDa antigen from keratinocyte culture
and a 97-kDa antigen from human skin extracts, but not BP180.
They noted that linear IgA disease antibodies reacted with this
antigen (Marinkovich et al, 1996). Further work showed that pa-
tients with generalized atrophic benign epidermolysis bullosa,
who were de¢cient in BP180, also failed to show reactivity to this
linear IgA disease antigen (Marinkovich et al, 1997). This sug-
gested that this antigen is the same as BP180; however, the lack
of immunoreactivity of sera with the intact BP180 antigen on im-
munoblot was not yet understood.
We next prepared mouse monoclonal IgG1 antibodies to the
LABD 97-kDa antigen.This was accomplished by using nitrocel-
lulose strips containing the 97-kDa antigen as the immunogen
implanted into mice. We were successful in using these mouse
monoclonal antibodies on an immunoa⁄nity column to purify
the 97-kDa antigen from epidermal extract. N-terminal amino
acid sequencing was then used to identify the amino acid se-
quence of the 97-kDa antigen. It showed identity with BP180
(Zone et al, 1998). The amino terminal of the 97-kDa antigen,
however, was within the extracellular portion of the molecule
and did not contain the MCW-1 region of BP180, which is the
antigenic epitope for BP patients. It is our conclusion from these
studies that the 97-kDa antigen is an epitope contained within
the 120-kDa protein identi¢ed by Marinkovich.We believe that
this represents a proteolytic fragment of BP180 that does not be-
come antigenic until proteolysis of the molecule occurs.This pro-
duces a fragment with an epitope that is distinct from the BP180
antigen recognized by BP sera (Fig 1).
As this unique epitope on BP180 seemed to be a central part of
the lamina lucida LABD, we decided to evaluate the reactivity of
these monoclonal antibodies in a mouse model. As noted above,
the 97-kDa antigen is not expressed in mouse skin but is ex-
pressed in human skin. In order to have a model in which the
antigen is expressed, we transplanted human neonatal foreskin
to adult athymic mice, allowing the grafts to mature for three to
¢ve weeks. Mouse IgG1 monoclonal antibodies, MAb 97^1 and
MAb 97^2, were puri¢ed from ascites. Following delipi¢cation,
the £uid was passed repeatedly over a protein G column and
eluted with 0.1 M acetic acid and neutralized withTris bu¡er. This
yielded puri¢ed antibodies with titers 41:10 000. We evaluated
the e¡ect of using MAb 97^1 and MAb 97^2 alone or in combi-
nation. One mg of each puri¢ed monoclonal Ab was injected
subcutaneously into the grafted athymic mice at 0 and 48 hours.
The combination injection involved 1 mg of each antibody. All
injections produced titers of 1:640 in the serum of the mice at
48 h, and titers could be maintained at 41:160 for 21 days. At
96 h, biopsies revealed intense deposition of IgG and comple-
ment at the BMZ and a basement membrane blister in some,
but not all, animals. A control group received an irrelevant IgG1
mouse monoclonal antibody (RSLD09, ATCC number HB-
8525, raised to prostate antigen) in an identical protocol. This
group did not develop serum BMZ antibody titers. The results
of these experiments are summarized inTable 2.
From this we concluded that: (1) both IgG MAb 97^1 and IgG
MAb 97^2 are pathogenic; that is, they produce microvesicles at
the BMZ in the skin grafts, indicating that the epitope recog-
nized by these antibodies is pathogenic; (2) vesicle formation
and eosinophil in¢ltration are increased when both antibodies
are administered simultaneously; (3) there is unexplained variabil-
ity in the production of microvesicles and in£ammation within
Table 2. Passive transfer of IgG mouse monoclonal antibodies
to the 97 kD LABD antigen to athymic mice with human
skin transplants
Antibodies
Administered
Number of
mice
Grafts with
BMZ split (%)
Grafts with
eosinophils (%)
MAb 97-1 &MAb 97-2 15 12 (80%) 6 (40%)
MAb 97-1 5 2 (40%) 1 (20%)
MAb 97-2 5 3 (60%) 0 (0%)
Control 5 1 (20%) 0 (0%)
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groups; (4) eosinophil numbers are variable in association with
vesicles; the size of the biopsy specimens did not allow further
processing for granule proteins; and (5) occasional control grafts
develop basement membrane zone blisters.
The development of spontaneous basement membrane zone
in£ammation and vesiculation in the control animals was of great
concern to us. Further evaluation of the human skin grafts re-
vealed that up to one-quarter of the mice demonstrated sponta-
neous IgM deposition in the graft, indicating an immune
response in some of the presumably immunode¢cient nude mice.
This greatly confused the passive transfer experiments, and we
decided to turn to SCID mice as recipients for the human skin
grafts in our later experiments with IgA monoclonal antibodies.
After evaluating the IgG hybridomas to the 97-kDa antigen,
we isolated IgA switch variants after exposing the hybridomas
to the mutagen acridine orange (ICR 191) (Paizi et al, 1995). IgA
hybridoma cells were then isolated either by £uorescein-activated
cell sorting (FACS) or by the ELISA spot assay (Spira and Schar¡,
1992). Brie£y, the IgG hybridomas were exposed to ICR 191 at
the level of 1 mg/ml for 24 h to achieve a 30%^40% death rate.
The surviving cells were then grown and subjected to either
FACS using £uorescein-conjugated antimouse alpha chain or
an ELISA that identi¢es positive clones in a 96-well plate using
appropriate antibodies and an alkaline phosphatase detection
system.
The IgA hybridomas were grown in Freunds incomplete adju-
vant primed Balb/c mice, and the resulting ascites £uid was admi-
nistered subcutaneously to SCID mice bearing human skin
grafts. Preliminary experiments indicated that a 14-day time
course was optimal and that injection of 1 mg of ascites on days
1, 3, 7, and 10 was necessary to maintain serum antibody titers
between 1:10 and 1:40. In the IgG experiments, we had noted that
the administration of both antibodies simultaneously, 97^1 and
97^2, produced vesiculation more frequently than separate ad-
ministration.Therefore, a combination of these antibodies was al-
ways used in our initial e¡orts to produce vesiculation with the
IgA monoclonals. The conditions necessary to maintain serum
titers for the IgA antibodies were di¡erent from those established
for the IgG antibody. IgA antibodies were cleared from the circu-
lation rapidly, so the animals required repeated dosing. The SCID
mice were never able to maintain serum IgA BMZ antibody
titers 41:40, as they could with the IgG BMZ antibodies.
Preliminary experiments also indicated that there was no in£am-
mation until after day 7, so we settled on a protocol involving a
4-mm punch biopsy taken on days 0 and 14. Direct immuno-
£uorescence and routine histology with H&E staining of forma-
lin-¢xed sections were performed. In an additional set of animals.
GMCSF (300 ng/mouse) was injected intradermally into the graft
on day 13 to see if activation of neutrophils or accentuation of
chemotaxis augmented the in£ammatory response (Zygmunt
et al, 1989; Metcalf et al, 1987).
The results of these experiments are shown inTable 3. It is im-
portant to realize that at no time in either the IgG or the IgA
experiments were visible vesicles or in£ammation identi¢ed. All
results are histologic and immunopathologic, the result of 4-mm
punch biopsies that were randomly obtained from grafts that
were approximately 3 cm in diameter. All biopsies were reviewed
without knowledge of the intervention used in that animal. At
baseline, all 32 mice used in this study had negative BMZ immu-
no£uorescence. This is important in view of the autoantibody
formation that occurred using athymic mice. Grafts were allowed
to mature for 3 to 5 weeks, so these baseline values represent the
negative control of the expected outcome with no antibody ad-
ministration. An IgA mouse monoclonal Ab is not available to
use as a negative control, as was done with the IgG experiments
(Table 3).
IgA deposition was evaluated by direct immuno£uorescence
(DIF) using FITC mouse antialpha chain. Following passive
transfer of the IgA antibody, there was strong positivity in the
graft in the 12 mice that received IgA alone and the in 7 mice that
also received GMCSF. The mice receiving GMCSF alone did not
show IgA deposition at the BMZ. No deposition of other immu-
noglobulin classes was ever seen in the grafted SCID mice. We
concluded that our protocol produces consistent and signi¢cant
IgA deposition at the BMZ.
Complement deposition was evaluated by DIF for mouse C3.
Occasional deposition was noted spontaneously at baseline (2/36).
Granular complement deposition was noted in 7 of 12 mice re-
ceiving IgA alone at day 14, with 3 of 12 demonstrated linear de-
position. Of the 7 mice receiving GMCSF plus IgA, 3 also
showed complement deposition, as noted in Table 3. GMCSF
alone produced complement deposition in one animal.We con-
cluded that complement deposition is irregularly present with
an inconsistent pattern. It was not selectively present in biopsies
where a vesicle was identi¢ed. For this reason it seems unlikely
that complement plays a role in any in£ammatory process in this
model.
Minimal neutrophil in¢ltration was noted in 9 of 32 animals at
baseline, but no animals demonstrated signi¢cant neutrophil in-
¢ltration, de¢ned inTable 3 as 2 ^ 3þ 0. Following the admin-
istration of IgA alone, 6 of 12 animals demonstrated signi¢cant
neutrophil in¢ltration, with in¢ltration of dermal papillae
(Fig 2). Two of seven animals receiving IgA plus GMCSF
demonstrated a similar signi¢cant in¢ltration, as well as 2 of 12
animals receiving GMCSF alone. From this, we conclude that the
passive transfer of IgA antibodies does produce neutrophil in¢l-
tration in a signi¢cant number of animals and this in¢ltration
occurs in dermal papillary tips. It does not seem to be accentuated
by GMCSF, although GMCSF alone does produce some in£am-
mation. Initial results reported in abstract form suggested that the
process isaccentuated by GMCSF.
We next turned our attention to the presence of BMZ separa-
tion in these specimens. Minimal vacuolization was noted in a
small number of animals, as reviewed in Table 3. Signi¢cant
BMZ separation (Fig 3), however, was noted in test animals after
administration of IgA or IgA plus GMCSF. A single animal re-
ceiving GMCSF alone did have signi¢cant vesiculation. It is not
surprising that in some situations GMCSF could produce vesicles.
Table 3. Passive transfer of IgA mouse monoclonal antibodies to the 97 kD LABD antigen to SCID mice with
human skin transplants
Evaluation Of Biopsy Baseline IgA alone IgAþGMCSF GMCSF alone
IgA BMZ () 32/32 0/12 0/7 12/12
BMZ (þ ) 0/32 12/12 7/7 0/12
Complement Granular 2/36 7/12 2/7 1/12
Linear 0/36 3/12 1/7 0/12
Neutrophils 1þ 9/32 4/12 4/7 3/12
2^3þ 0/32 6/12 2/7 2/12
Vacuoles Present 4/36 0/12 0/7 1/12
Blister 1þ 1/36 1/12 3/7 3/12
2^3þ 0/36 4/12 1/7 1/12
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It is chemotactic for neutrophils, and BMZ separation is likely
induced by neutrophil enzymes. We conclude that at least one-
third of the animals receiving IgA alone tested in this manner
developed signi¢cant BMZ vesiculation with signi¢cant neutro-
phil in¢ltration. This indicates that IgA is pathogenic in this
model. The fact that positive ¢ndings were noted in only a min-
ority of animals makes it di⁄cult to study the mechanism of this
process in detail. We suspect that two issues are important and
need to be investigated. First, only a small portion of the graft
was sampled. Sampling of the entire graft may identify in£am-
mation and vesiculation in grafts that would otherwise be called
negative. Second, the antibody titers in the IgA model are always
much lower in the IgG model.We are currently exploring new
experimental protocols that will raise the serum antibody levels
to titers comparable to those in the IgG experiments.
SUMMARY
IgA is present in the skin of a number of dermatoses, suggesting
that it is responsible for the associated in£ammatory events. The
mechanism for this process is unclear, but it is likely to involve
IgA-mediated neutrophil in¢ltration. Elucidation of the mechan-
ism will require a mouse model.We have established a model for
LABD as a prototype disease to be studied. Our experiments to
date indicate that this model is feasible and that IgA deposition
and in£ammation can be produced by passive transfer of mouse
IgA antibodies against a linear IgA antigen.
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